William K. Oh, MD - Chair’s Take on Innovation in Prostate Cancer: Thoughts on New Evidence - a podcast by PVI, PeerView Institute for Medical Education
from 2020-07-17T18:00
Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education